Heart Failure in the Era of Precision Medicine
Published: September 12, 2019
- One in five people in the U.S. will develop heart failure (HF) in their lifetime
- Early diagnosis and better understanding of HF pathophysiology are critical to optimal treatment and outcomes.
- This statement describes the current state of the “omics” — genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, and microbiomics — as they relate to HF and explores current and potential applications of “omics” data for precision medicine.
Supporting Materials
- Commentary: Precision Medicine for Heart Failure: using "omics" technologies to find the road to personalized care by 1. Kory J. Lavine MD, PhD and 2. Charles E. Canter, MD
- Top Things to Know: Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association
- AHA News: A guide to a custom-tailored era of heart failure treatment
Recommended Reading
- 2018 American Heart Association Precision Medicine Platform
- 2018 Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine
- 2018 Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine
- 2017 The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction
- 2017 Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure
- 2017 Focused Update of the 2013 Guideline for the Management of Heart Failure
- 2013 Guideline for the Management of Heart Failure